Immune responses regulation following antitumor dendritic cell-based prophylactic, concurrent, and therapeutic vaccination

被引:3
|
作者
Samadi-Foroushani, Morteza [1 ]
Vahabpour, Rouhollah [2 ]
Memarnejadian, Arash [2 ]
Namdar, Afshin [1 ]
Khamisabadi, Masoumeh [1 ]
Sadat, Seyed Mehdi [2 ]
Asgarian-Omran, Hossein [1 ]
Azadmanesh, Kayhan [2 ]
Kokhaei, Parviz [3 ,4 ]
Aghasadeghi, Mohammad Reza [2 ]
Hadjati, Jamshid [1 ]
机构
[1] Univ Tehran Med Sci, Dept Immunol, Sch Med, Tehran, Iran
[2] Pasteur Inst Iran, Tehran, Iran
[3] Semnan Univ Med Sci, Dept Immunol, Semnan, Iran
[4] Karolinska Univ Hosp, Immune & Gene Therapy Lab CCK, Stockholm, Sweden
关键词
Dendritic cell; Regulatory T cell; Foxp3; IDO; Tumor immunotherapy; INDOLEAMINE 2,3-DIOXYGENASE; T-CELLS; IN-VIVO; CANCER; IMMUNOTHERAPY; INDUCTION; TOLERANCE; IDO; IMMUNOSUPPRESSION; ACTIVATION;
D O I
10.1007/s12032-010-9720-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
There is ample evidence in favor of various immunosuppressive mechanisms that weaken antitumor immune responses and affect currently used immunotherapies. Induction of regulatory T cells (Treg) and secretion of indoleamine 2,3-dioxygenase (IDO) by tumor tissue are considered as two main mechanisms of tumor immune escape. However, little is known about the contribution of these mechanisms on the modulation of dendritic cell vaccine-mediated antitumor response. To address this concern, we assessed Treg's infiltration and the expression of Foxp3 and IDO genes in tumor microenvironment following dendritic cell-based antitumor immunotherapy of mice in different protocols of prophylactic, concurrent, and therapeutic vaccination. According to cytotoxicity assay, the vaccinated mice exposed efficient induction of splenic CTLs in all groups. However, only the mice immunized in prophylactic regimen significantly retarded the growth of tumor cells. Interestingly, the Treg content of tumor samples and transcriptional level of both Foxp3 and IDO genes were reduced in this group, while animals that received the vaccine in concurrent and therapeutic protocols showed increase in tumor-infiltrating Tregs and mRNA levels of Foxp3 and IDO. Accordingly, higher expression of these genes resulted in more inhibition of antitumor response. Our findings indicate that tumor progression may enhance the immunoregulatory response and hence emphasize to the effectiveness of vaccination in early stages of tumor growth for avoiding induction of such regulatory responses.
引用
收藏
页码:S660 / S666
页数:7
相关论文
共 50 条
  • [1] Immune responses regulation following antitumor dendritic cell-based prophylactic, concurrent, and therapeutic vaccination
    Morteza Samadi-Foroushani
    Rouhollah Vahabpour
    Arash Memarnejadian
    Afshin Namdar
    Masoumeh Khamisabadi
    Seyed Mehdi Sadat
    Hossein Asgarian-Omran
    Kayhan Azadmanesh
    Parviz Kokhaei
    Mohammad Reza Aghasadeghi
    Jamshid Hadjati
    [J]. Medical Oncology, 2011, 28 : 660 - 666
  • [2] Dendritic Cell-Based Therapeutic Vaccination for HIV
    Benito, Jose M.
    [J]. AIDS REVIEWS, 2013, 15 (01) : 62 - 62
  • [3] Dendritic cell-based therapeutic vaccination for acute myeloid leukemia
    Anguille, Sebastien
    Van Tendeloo, Vigor
    Berneman, Zwi
    [J]. BULLETIN DU CANCER, 2012, 99 (06) : 635 - 642
  • [4] Dendritic Cell-Based Approaches for Therapeutic Immune Regulation in Solid-Organ Transplantation
    Vassalli, Giuseppe
    [J]. JOURNAL OF TRANSPLANTATION, 2013, 2013
  • [5] Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination
    Galea-Lauri, J
    Wells, JW
    Darling, D
    Harrison, P
    Farzaneh, F
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2004, 53 (11) : 963 - 977
  • [6] Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine
    Ohshio, Yasuhiko
    Teramoto, Koji
    Hanaoka, Jun
    Tezuka, Noriaki
    Itoh, Yasushi
    Asai, Tohru
    Daigo, Yataro
    Ogasawara, Kazumasa
    [J]. CANCER SCIENCE, 2015, 106 (02) : 134 - 142
  • [7] Dendritic cell-based vaccination against cancer
    Saito, Hiroaki
    Frleta, Davor
    Dubsky, Peter
    Palucka, A. Karolina
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2006, 20 (03) : 689 - 710
  • [8] Dendritic cell-based vaccination in solid cancer
    Stift, A
    Friedl, J
    Dubsky, P
    Bachleitner-Hofmann, T
    Schueller, G
    Zontsich, T
    Benkoe, T
    Radelbauer, K
    Brostjan, C
    Jakesz, R
    Gnant, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) : 135 - 142
  • [9] Dendritic cell-based vaccination against cancer
    Schuler, G
    [J]. JOURNAL OF GENE MEDICINE, 2003, 5 (03): : S28 - S29
  • [10] Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell-Based Vaccination
    Aarntzen, Erik H. J. G.
    De Vries, I. Jolanda M.
    Lesterhuis, W. Joost
    Schuurhuis, Danita
    Jacobs, Joannes F. M.
    Bol, Kalijn
    Schreibelt, Gerty
    Mus, Roel
    De Wilt, Johannes H. W.
    Haanen, John B. A. G.
    Schadendorf, Dirk
    Croockewit, Alexandra
    Blokx, Willeke A. M.
    Van Rossum, Michelle M.
    Kwok, William W.
    Adema, Gosse J.
    Punt, Cornelis J. A.
    Figdor, Carl G.
    [J]. CANCER RESEARCH, 2013, 73 (01) : 19 - 29